Who is sponsoring NCT06933212?

NCT06933212 is sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta.

What drugs are being tested in NCT06933212?

Interventions in NCT06933212: Mediterranean Diet with Extra Virgin Olive Oil, Mediterranean Diet with Walnuts, Low-Fat Control Diet.

What condition does NCT06933212 study?

NCT06933212 studies Cerebral Amyloid Angiopathy, CAA - Cerebral Amyloid Angiopathy.

Is NCT06933212 still recruiting?

NCT06933212 is currently recruiting now. Last updated 18 April 2025.

Last reviewed 2025-04-18 · How we verify

NCT06933212: DIETETICA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy.

Recruiting now Last updated 18 April 2025

What this trial tests

trial testing Mediterranean Diet with Extra Virgin Olive Oil in Cerebral Amyloid Angiopathy in 86 participants. Currently enrolling.

Timeline

10 October 2024

Primary endpoint
31 March 2025

31 July 2026

Quick facts

Lead sponsor	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	86
Start date	10 October 2024
Primary completion	31 March 2025
Estimated completion	31 July 2026
Sites	1 location across Italy

Drugs / interventions tested

Mediterranean Diet with Extra Virgin Olive Oil
Mediterranean Diet with Walnuts
Low-Fat Control Diet

Conditions studied

Cerebral Amyloid Angiopathy — all drugs for Cerebral Amyloid Angiopathy →
CAA - Cerebral Amyloid Angiopathy — all drugs for CAA - Cerebral Amyloid Angiopathy →

Sponsor

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta — full company profile →

Who can join

18 and older, any sex, with Cerebral Amyloid Angiopathy or CAA - Cerebral Amyloid Angiopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is divided into two phases: Phase 1 (observational) and Phase 2 (dietary intervention). The goal of Phase 1 is to assess the nutritional status and dietary habits of two cohorts of patients with CADASIL and CAA. A specific aim is to evaluate adherence to the Mediterranean Diet. The objectives include analyzing patients' nutritional status, lean and fat mass, basal metabolism, and total energy expenditure. It also aims to assess the relationship between adherence to the Mediterranean Diet and the onset of stroke and cognitive decline, as well as examine stroke severity (ischemic or hemorrhagic) and its association with Mediterranean Diet adherence (MEDAS questionnaire). Additionally, the study will explore the link between diet adherence and cognitive deficits, and measure changes in biological and anthropometric parameters as a result of adopting the Mediterranean Diet. Phase 2 is an interventional dietary study designed to evaluate the effects of the Mediterranean Diet, enriched with either extra virgin olive oil or walnuts, on stroke incidence and cognitive decline in patients with CAA and CADASIL.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Cerebral amyloid angiopathy: a narrative review.
Noto NM, Speth RC, Robison LS. · · 2025 · cited 4× · PMID 41035821 · DOI 10.3389/fnagi.2025.1632252
Impact of the Mediterranean Diet on stroke incidence and cognitive impairment in CADASIL and CAA patients: the DIETETICA study.
Strazzabosco C, Storti B, Marinoni G, Carolina T, et al · · 2025 · PMID 41377571 · DOI 10.3389/fnut.2025.1682134

Verify or expand the search:

Other recruiting trials for Cerebral Amyloid Angiopathy

Currently open trials in the same condition.

NCT06393712 — A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy · Phase 2 · recruiting
NCT05734378 — Prognosis of Cerebral Small Vessel Disease · recruiting
NCT04204642 — SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA) · recruiting
NCT06128824 — High Frequency Imaging in Cerebral Amyloid Angiopathy · active not recruiting

Other Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta trials

Trials by the same sponsor.

NCT07168850 — Focused Ultrasound Unilateral Pallidotomy for Medication-Refractory Limb Dystonia · NA · recruiting
NCT06699095 — Home Rehabilitation As Continuity of Care in MS · NA · recruiting
NCT06584097 — COMparative Performance of General Purpose Models · recruiting
NCT07427940 — Omic Profile in Autism Spectrum Disorder: From Cellular Level Towards Future Treatments · NA · recruiting
NCT06844838 — FASt Track in Elective Neurosurgery: the Role of Low Propofol Bis-NOL Guided General Anaesthesia for Full, Early and Saf · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06933212 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Last refreshed: 18 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06933212.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing